Aspire Biopharma Holdings

Company snapshot

Aspire Biopharma is developing next generation absorption of medicine that will have a significant impact on the opioid crisis. Our nano technology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract. Aspire’s technology comes from a new mechanism of action (absorption pathway) which allows for instant absorption in the mouth. Benefits of “instant absorptio

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Aspire Biopharma Holdings. Not investment advice.

• Peer + 0 momentum

  Rhythm Pharmaceuticals Netherlands

  TA overlap score 34.6

Recent activity

Latest pipeline, patent, and corporate events for Aspire Biopharma Holdings.

1. Jun 8, 2026 Clinical update

   Retinol — Phase 2

2. Jun 8, 2026 Clinical update

   Regadenoson — Approved

3. Jun 8, 2026 Clinical update

   Pulse Sequence — Approved

4. May 23, 2026 Clinical update

   ACT-20-MSC — Phase 2

5. May 23, 2026 Clinical update

   AdreView — Approved

View all clinical trial activity →

• What is Aspire Biopharma Holdings?

  Aspire Biopharma is a biotech organization headquartered in Humacao, USA. It trades on NYSE under ticker ASBP. Primary therapeutic focus areas include Coronary Artery Disease, Bronchopulmonary Dysplasia, Heart Failure, COVID-19 Pneumonia, Blood Pressure. NovaPharmaNews links 8 cl

• Is Aspire Biopharma Holdings publicly traded?

  Yes. Aspire Biopharma Holdings is listed with ticker ASBP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Aspire Biopharma Holdings develop or market?

  We link 8 drug profile(s) where Aspire Biopharma Holdings is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aspire-biopharma-holdings#company-drugs.

• What are the latest developments for Aspire Biopharma Holdings?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Aspire Biopharma Holdings focus on?

  Aspire Biopharma Holdings focuses on Coronary Artery Disease, Bronchopulmonary Dysplasia, Heart Failure based on our analysis of their pipeline programs and drug development activities.